As a comprehensive pharmaceutical manufacturer with high and new
technology, Beijing Zizhu Pharmaceutical Co., Ltd. was reformed in
2000 from Beijing 3rd Pharmaceutical Factory where was established
in 1969. Integrated with manufacture, management and R&D, the
corporation has 5 GMP production workshops, quality control center,
product R&D center, staff training center and other auxiliary
facilities. The headquarter is located at Chao Yang North Road,
Chao Yang District, covering an area of 122,000 m2, with a
construction area of 60,000 m2 and a ratio of 40% green space. The
corporation has the registered capital of 380,639,600 yuan and more
than 1,300 staff. The total capital is up to 675,000,000 . In 1999,
the corporation was the first one across the country that obtained
the national GMP authentication in one time with 8 types of
medicine, which are tablets, capsules, modest capacity injection
tablets powder injection, sustained-release capsule, gels,
transdermal patches, and APIs from 7 workshops. In addition, the
corporation obtained the ISO9001: 2000 International Quality
Management System Authentication and Excellent Award of Beijing
Municipal Quality Management in 2001, ISO14001 Environment
Management System Authentication in 2002, OSHAS18001(Occupational
Safety and Health Administration) in 2004, Outstanding Award of
Beijing Municipal Quality Management in 2005.
Zizhu specializes in the R&D and manufacture of five series
products, which are family planning medicine, reproductive health
medicine, ophthalmic medicine, health care products and biological
products. Zizhu is now the designated scientific R&D and
manufacture center of medicine for family planning and reproductive
health. As a fact, Zizhu has achieved the scale priorities on
R&D and manufacture of medicine for family planning and
reproductive health, gaining considerable market share in China.
For the time being, Zizhu has been listed as one of the famous
enterprises in the reproductive medicine industry around the world,
and approved by Beijing municipal government as the new and high
technology enterprise in Beijing.
Zizhu has paid great priorities to the R&D of new products.
Based on the development of domestic and international medical
scientific research coupled with the manufacturers situation of the
same industry and products, the corporation takes advantages of the
priorities of hormone steroid research that has been formed so many
years, higher level industrial platform as well as the advanced GMP
management to ensure the implementation of new products R&D
strategy. In 2001 the corporation boldly introduced the advanced
product technology, and submitted the report for approval and
implemented industrial manufacturing simultaneously. It
successfully developed and manufactured national patent product-the
third category new medicine of ophthalmology-Compound Anisodine
Injection and brought the hope for the ophthalmology patients. In
2001 the corporation R&D team overcame the technological
difficulties and completed the approval and industrialization of
national 2nd category new medicine Mifepristone tablets concomitant
drug - Misoprostol tablet, saving considerable foreign currency and
cut down the cost. The sales reached up to a few hundred million
yuan in 2001.
Following in tow with the implementation of three innovations on
technology, management and mechanism respectively, Zizhu has
fulfilled the rapid development of the enterprise. Supported by its
scientific innovation, it has established the corporation
relationship integrated with manufacture, study and research with
some famous domestic and oversea scientific research institutes and
universities. It has formed its unique products development
mechanism and products series. The new products launching on the
market has been step by step, along with one or two new products
every year that possess high technology to bridge the gap. Through
the innovation on both management and system, the establishment of
modern enterprise system, as well as the people-oriented modern
management style, the corporation has achieved constant progress on
its comprehensive economic performance in recent successive years.
The corporation has a fully owned affiliated marketing company,
which is Beijing Zizhu Management Co. Ltd. coupled with several
subsidiaries. It has shares in Beijing Hanmi Pharmaceutical Co.
Ltd.
Zizhu is distinctive in pursuit of the pioneer of the domestic new
medicine R&D, and it has been lobbying for entering into
international markets and enthusiastically made contacts with the
relevant technological companies which are world leaders and
establishes coordinating relations. In 1980s, Zizhu cooperated with
Pfizer and introduced the world leading medical equipments,
manufacturing technology and management experiences and
manufactured cephalosporin anti-biotic and won china market. Zizhu
is the first one introducing the world advanced medicine
manufacturing equ
